<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="Janssen | Remicade - REMICADE for paediatric IBD">
<title>Janssen | Remicade - REMICADE for paediatric IBD</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<style type="text/css">
	.content .feature { width: 106.5%;  height:340px; margin-left:-60px; background-image:url('img/graph_2.png'); position:relative; }
	.content > p { letter-spacing:-0.02em; margin-bottom:4px; }
	.footnote { width:102%; }
	
	/* bottom menu */ 
	.footer-menu .height > ul { left:-9.5em; }
	.footer-menu .height > ul { width:170px; }
	.footer-menu .height > ul:after { left:9.5em; }
	
	
</style> 
</head>
<body>
	<section class="content-wrapper sides">
    	<header>
        	<span class="remicade-logo right"></span>
            <span class="section-label">Crohn’s<br />disease</span> 
        	<div class="btn-menu">
                <ul class="popup-menu">
                    <li class="btn-home"><i></i></li>
                    <li class="btn-ref circle"></li>
                    <li class="btn-mpi circle"></li>
                    <li class="btn-info circle"></li>
                </ul>
            </div>
        </header>
    	<article class="inner-wrapper">
       		<div class="content">
                <h2 class="g-line">REMICADE and quality of life improvement<sup>1</sup></h2>
                
                <p>REMICADE significantly improved quality of life<sup>†</sup> in children with moderate-to-severe Crohn’s<br />disease
through 1 year of follow-up<sup>1</sup></p>
                <p class="orange">Mean quality of life improvements as measured by IMPACT III score from baseline at weeks 10, 30 and 54<sup>1</sup></p>
                <div class="feature"></div>
                 
        <div class="footnote">
        <span class="g-line">Adapted from Hyams J <em>et al</em>, 2007.<sup>1</sup><br />
<sup class="b">&dagger;</sup>As measured by IMPACT III, a health-related quality-of-life questionnaire specifically developed to assess quality of life in paediatric patients with inflammatory bowel disease, validated for use in ages 10-17.
The IMPACT III scores range from 35 to 175, with higher scores indicating better quality of life.<sup>1</sup></span>
           <ul class="list">
 			<li>The mean IMPACT III score at week 10 had improved significantly from baseline (mean increase of 23.9; p&lt;0.001)<sup>1</sup></li>
			<li>Similarly, the mean IMPACT III scores at weeks 30 and 54 had improved significantly from baseline<br />
(p&lt;0.001 for both comparisons)<sup>1</sup></li>
</ul>
        </div>
            
        	</div>
            
            <!--footer menu -->
            <ul class="footer-menu">
            	<li class="response mid">Response <br />&amp;&nbsp;Remission</li>
                <li class="qol mid active">QoL</li>
                <li class="steroids mid">Steroids</li>
                <li class="height">
                	<ul>
                        <li class="hs">Height Status</li>
                        <li class="ih">Improved height status</li>
                	</ul>
                	<span>Height <br />Status</span>
                </li>
            </ul>
       
        </article>
        <div class="popup ref">
            <h3>Reference</h3>
            <ol>
                <li class="ref1">Hyams J <em>et al</em>. Gastroenterology 2007; 132: 863–873.</li>
            </ol>
        </div>
        <!--   Study design  -->
    	<div class="popup study-design">
    		<h3>Study design</h3>
        REACH: 112 paediatric patients with moderately to severely active Crohn’s disease and a Paediatric
Crohn’s Disease Activity Index (PCDAI) score &gt;30 received REMICADE 5 mg/kg at weeks 0, 2 and
6. Patients responding to treatment at week 10 were randomised to REMICADE 5 mg/kg every 8
or 12 weeks through week 46. A concurrent immunomodulator was required. Clinical response and
clinical remission were evaluated at weeks 10, 30 and 54. Adapted from Hyams J <em>et al</em>.<sup>1</sup>
    	</div>
    <!-- popup main menu-->
        <aside class="main-menu animated">
        <span class="close circle"></span>
            <ul class="level1 paed">
                <li class="cd">
                    <ul class="play">
                        <li class="home" data-slide="home">
                            <span></span>
                            <span></span>
                            <span></span>
                        </li>
                        <li data-slide="cd">Crohn’s<br />disease</li>
                        <li data-slide="uc">Ulcerative<br />Colitis</li>
                    </ul>
                </li>
                <li class="common">
                    <ul class="play">
                        <li data-slide="st">Safety<br />& Tolerability</li>
                        <li data-slide="do">Dosing</li>
                        <li data-slide="ad">Adherence</li>
                        <li data-slide="pr">Preference</li>
                    </ul>
                </li>
            </ul>
        </aside>

    </section>
<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){
		
		goToSlide('footer-menu .response', 'P-IBD1601-Response-and-remission');
		//goToSlide('footer-menu .qol', 'P-IBD1602-QoL');
		goToSlide('footer-menu .steroids', 'P-IBD1603-Steroids');
		goToSlide('height .hs', 'P-IBD1604-Height-status');
		goToSlide('height .ih', 'P-IBD1605-Improved-height-status');
		
		//references
		goToSlide('ref1', 'Hyams2007');
	})

</script>
</body>
</html>
